Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 17, 2025

FDA grants orphan drug status for Korro Bio’s AATD therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation for Korro Bio’s KRRO-110 to treat alpha-1 antitrypsin deficiency (AATD).

FDA grants orphan drug status for Korro Bio’s AATD therapy